This condition is defined as local allergic rhinitis. However, the reported presence of nasal specific immunoglobulin E (nspIgE) among NAR is variable. The aim of this review was to summarize the studies which reported the presence of nspIgE among patients diagnosed as NAR. Embase (1947-) and Medline (1946-) were searched until 6th June 2017. A search strategy was utilized to identify studies on nspIgE among patients with NAR. The target population was patients with symptoms of rhinitis, but negative systemic allergen sensitization. Studies with original data on detectable nspIgE among the NAR population were included. Meta-analysis of single proportions as a weighted probability %(95%CI) was performed. Heterogeneity was explored amongst studies.
Introduction
Diagnosis of allergic rhinitis (AR) involves demonstrating the presence of specific Immunoglobuin E (spIgE) in a person with nasal symptoms. Standard allergology evaluation employs systemic assessments, either skin prick testing (SPT) or by serological detection of spIgE (1) . Those who test negative for these systemic tests are diagnosed with non-allergic rhinitis (NAR).
However, there has been compelling evidence suggesting that in certain NAR patients, spIgE can be present only in the nose, and is not detectable via routine systemic blood assessment or SPT. The term entopy or local allergic rhinitis (LAR) (2) has been used to describe this group of rhinitis patients. In published studies, there is a very wide range in the percentage of NAR patients who have a positive result for the presence of nasal C o r r e c t e d P r o o f spIgE (nspIgE) (3) .
A systematic review of the literature was performed to identify studies that investigated nspIgE among patients with NAR. The primary objective was to assess for evidence of nspIgE among rhinitis patients with negative systemic allergy. The secondary objective was to determine if presence of nspIgE was influenced definitions of NAR.
Materials and methods
A systematic review was performed to identify studies on patients diagnosed as NAR with reported outcomes on nasal sampling for nspIgE. This review was done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (4) . Methods from the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy (5) was followed where applicable.
Eligibility criteria
Studies which assessed for nspIgE among rhinitis patients with negative systemic allergy status were included. Participants were rhinitis patients of any age, with a history of physician diagnosed rhinitis or chronic symptoms of rhinitis. These patients must have undergone systemic evaluation for allergy (either SPT or serum spIgE) and nasal sampling which was tested for nspIgE. Studies were excluded if the nasal test did not include any nspIgEs for aeroallergens, or if participants were diagnosed with chronic rhinosinusitis, asthma without rhinitis or infectious rhinitis. Only studies with data reported as proportions were included. Study designs were diagnostic studies of either case series, case-control or cross-sectional design. Only manuscripts published in English were considered; case reports, reviews, guidelines, letters and editorials with no original data were excluded as well as animal studies. The outcome of interest was the proportion of patients with detectable nspIgE among the NAR population.
Information sources
A systematic electronic search was performed on both the Embase (1947-) and Medline (1946-) databases until 6th June 2017.
A search strategy was designed for each database (Appendix 1) to identify all studies on a rhinitis population with nasal assessment for allergy. Missing studies were searched manually from the bibliography of included studies.
Study selection
The search results were reviewed by two authors (AWH and RJH) and selected according to the eligibility criteria. Titles were screened for relevant articles followed by abstract review. Uncertain abstracts were then discussed between the reviewers. Full texts of the selected abstracts were then analyzed and excluded if they did not fulfil the selection criteria.
Data collection
An Excel standardized data-sheet was used to extract relevant data from the selected studies. Variables recorded were: study type, study location, number of subjects, definition of NAR and its baseline characteristics (when available), type of sampling methods, timing of sampling, test used to measure nspIgE and the outcome.
Data synthesis
Descriptive data was presented in percentages and proportions.
Meta-analysis of single proportions was done for a selected group of studies. This data was analyzed using Excel 2016 (Microsoft, Redmond, WA, USA) with a statistical add-on application package MIX2.0 (BiostatXL, 2016, CA, USA) (6) . The frequency of detectable nasal spIgE among NAR population (n/N) in these studies was transformed using the Freeman Tukey transformation. Data output was generated as a weighted probability both within individual studies and as overall cumulative tests.
The data was presented as a percentage with a 95% confidence interval. Heterogeneity was assessed by the I2 test and explored for discrepancies.
Results

Study selection
The search strategy yielded a total of 2286 studies. Studies were reduced to 1690 after 596 duplicates were removed. These titles were then screened which left 500 abstracts for assessment.
There were 135 full text studies which were assessed for eligibility, of which 21 studies were included ( Figure 1 ). Of these, four studies were duplicated. These studies involved 648 participants with NAR.
Characteristics of included studies
The included studies consisted mainly of case controls (n=16) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) and case series (n=5) (23) (24) (25) (26) (27) . All were original articles except for one conference abstract (26) . The characteristics of included studies are available in Appendix 2.
Population
Studies were conducted in Europe except for seven studies (15, 16, 18, 22, 24, 26, 27) . All studies included NAR populations with minimum criteria of rhinitis symptoms but negative serum spIgE and/or skin prick test. The majority of studies were on adults while six studies (8-10, 14, 23) involved children. There were two studies which exclusively studied patients with non-allergic rhinitis with eosinophilia (NARES) (7, 24) .
Systemic tests to rule out allergy among NAR
All studies defined their NAR population as having symptoms of rhinitis but negative systemic tests. There were 13 studies which used dual systemic test (both negative serum spIgE and skin C o r r e c t e d P r o o f
Definition of NAR within the target population
The baseline characteristics of the NAR population were available for 13 studies and assessed. This descriptive data was grouped into either positive, negative or uncertain clinical allergic characteristics. Studies were defined to have NAR patients with positive allergy characteristics when there was either an identifiable aeroallergen which triggered the nasal symptoms (10, 12, 13, 16, 20, 21, 23) or if there was seasonality of symptoms (10, 20, 21, 23) . Studies were defined to have patients with negative allergy characteristics if a history of allergy was specifically ruled out (no family history of allergy, no allergen triggers or no allergic co-morbidities) (7, 18, 24) . Studies which did not give the above details but gave data which could suggest allergy (co-morbidities and family history of atopy) were defined as having uncertain allergic characteristics (11, 19, 27) (Table 1 ). Other studies did not report any baseline characteristics of their NAR population (8, 9, 14, 15, 17, 22, 25, 26) .
Intervention: sampling method
Most studies sampled the nasal secretions to assess for nspIgE except for seven studies (one study biopsied the inferior turbinate tissue (16) and two studies performed nasal mucosal sampling (either using a cytology brush (27) or nasal curette (11) , three studies used a unique method of in-situ testing (9, 10, 14) and one study did not specify it's sampling method (26) ). In-situ tests involved incubation of solid phase coupled allergen directly on nasal mucosa. Nasal secretions were sampled either by nasal lavage/washings (13, (19) (20) (21) 23) or direct collection of nasal secretions.
Direct collection of nasal secretion was done either by collecting spontaneous secretions (24) , by suctioned secretions (22) , by absorbing nasal secretions in the nasal cavity (using filter paper (12, 15) prick test) (7, 11-13, 16, 18-24, 27) to rule out systemic sensitization. The other studies used only a single test, where six studies defined their NAR population as having negative SPT (9-10, 14, 15, 17, 26) and two studies defined NAR as having negative serum spIgE (8, 25) . 
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or cotton wool pieces (7, 17, 18) or by first stimulating the nasal cavity with hypertonic solution followed by collection of produced nasal secretions (8, 25) . The summary of nspIgE found in secretions, nasal mucosa or tissue are summarized in Figure 2 .
Type of allergen
There were three studies which tested for pollen allergens (20, 21, 23) seven studies tested for dust mites or house dust (8, 12, 13, 15, 16, 19, 24) while the other studies tested for a panel of common aeroallergens (7, 9, 10, 14, 18, 22, 25, 27) .
Time of sampling
Most studies performed nasal sampling at random (no specified point of time) except for four studies, which sampled the nasal mucosa at both baseline period prior to and after nasal allergen provocation test (NAPT) (13) , after NAPT only (21) , or during the pollen season (10, 20) .
Positivity criteria for detectable nasal specific Immunoglobulin E
The presence of nspIgE was tested using commercial lab methods by either radioimmunoassay (and utilized the radioallergosorbent test (RAST), mostly during the pre-90s period), or used the fluoroenzyme immunoassay (FEIA) (ImmunoCAP®/ uniCAP® system). The exceptions were two studies which used the in-situ methods and measured the response directly based on their own protocol. The RAST method reported the outcome using the ordinal class system (class 0 to 4). Class 0 being undetectable. Class 1 and above was determined as positive presence of nspIgE. The FEIA reported its outcome as continuous data, where a value of 0.35kU/L or more was used to define presence of nspIgE (13, 14, (19) (20) (21) 23) . There were two studies which used a lower cut-off of 0.1kUA/L (27) and 0.17kUA/L (11) .
Meta-analyses: presence of nasal spIgE in nasal secretions
Only studies which sampled nasal secretions (n=14) (7) (8) (12) (13) 15, (17) (18) (19) (20) (21) (22) (23) (24) (25) were pooled for a total of 484 NAR subjects. The pooled summary estimate for the presence of nspIgE in nasal secretions among NAR was 10.2 (7.4-13.4) %.
Heterogeneity of studies
This group of studies were heterogenous with I2 value 84.7(76.9 -89.9)%.
Subgroup analysis
A subgroup analyses was done to explore the heterogeneity. To 
Discussion
The presence of nspIgE among patients with NAR showed extreme variability with reported values from 0 to 100%. This highly variable result was partly due to the definition of NAR. Patients who lacked a suggestive allergy history and had negative systemic allergy tests, on summary proportions, had zero probability of having detectable nspIgE (0 (0-3.1) % (28) . Studies have also shown that a positive family history of atopy was significantly higher among patients with LAR compared to those with NAR (29, 30) . Furthermore, prior studies which reported more than 50% prevalence of LAR diagnosed by NAPT, involved subjects with seasonality of symptoms (20, 23, 31) or identified an allergen trigger (32) . Potentially, only those with a suggestive allergic history but negative SPTs and/or serum spIgEs, warrant further investigation in order to embark on allergen reduction interventions or immunotherapy. Prior studies have confirmed that LAR and AR share similar clinical characteristics, underlying inflammatory pattern and both respond well to intranasal steroid as well as immunotherapy (20, 33) . This leads to a question whether good response to intranasal corticosteroids could differentiate LAR from AR. Similar to AR, topical nasal steroids and oral antihistamine is the recommended treatment of LAR (34) . AR generally responds well to intranasal corticosteroids, however studies on its benefit in NAR had been variable. This may be due to lack of identification of NAR subtypes, including LAR (35) . Up to date, LAR is considered a NAR subtype, owing to its negative systemic sensitization (36) . In this current review, the majority of studies were conducted in Europe. Of note, studies conducted in Spain (8, 13, (19) (20) (21) 23) gave more consistent results where most investigations detected 12-30% nasal spIgE in nasal secretions of their NAR patients. Apart from patient selection with history suggestive of allergy, geographical variations may be a contributing factor. The prevalence of LAR diagnosed based on NAPT had been reported to be lower in Asian countries compared to western countries (33) . This may be due to climate factor where seasonal allergens more closely associated with LAR (37) , are more prevalent in temperate conditions. Furthermore, only few studies have been conducted outside of Europe which may be a confounder.
LAR is thought to occur due to local spIgE synthesis in the nasal mucosa itself. The mechanism of allergen spIgE production (class switch recombination, somatic hypermutation, B cell affinity maturation before differentiating into IgE producing plasma cells) have been studied in the human nasal mucosa (38) .
These studies show compelling evidence that the nasal mucosa The weighted probability of detecting nspIgE in the individual studies with 95% confidence intervals (error bars) was represented as boxes.
Diamonds represented pooled summary estimates for each definition of NAR.
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is a capable primary site for highly selected and refined spIgE production. It has also been reported that only 1% of the spIgEs in serum are derived from peripheral blood mononuclear cells suggesting other major sites of spIgE production (39) . Locally produced allergen spIgE will first bind to nasal tissue mast cells and the excess spIgE will be released into the nasal secretions and circulation (40) and these spIgE may escape systemic detection.
Therefore, assessment for allergy at the primary site has become an increasingly important test. Unfortunately, local nasal assessment is marred by some yet unresolved complexities.
NAPT is the established method to diagnose LAR. However, whether an induced allergen provocation in a controlled setting reflects the disease state upon natural exposure remains questionable. NAPT is also time consuming, requires special patient preparation and trained personnel to perform the procedure.
Furthermore, only one allergen can be tested at a time and the methodology remains broad with differing recommendations regarding allergen dose, mode of application and interpretation of nasal response (38) . A relatively non-invasive method to sample the nasal mucosa would be a much more practical alternative.
However, this method of assessment is still in research phase.
One of the issues faced with testing for nasal spIgE is the low sensitivity. In this study, 10% of NAR population was estimated to have detectable nasal secretion spIgE which is less than half of previously reported value in another systematic review where 24.7% of patients diagnosed as NAR had a positive NAPT (37) . This is due to the low SpIgE concentrations detected in nasal samples compared to serum (8, 41, 42) . This low concentration could be a (21, 23) . Also, little is known about local nspIgE half-life and degradation process which may differ from serum spIgE. Therefore, the cut-off value of 0.35kUA/L determined for serum may not be suitable for nasal samples. Further studies are still needed to define the role of nspIgE in determining LAR and establish its diagnostic utility and appropriate threshold.
Conclusion
Local allergic rhinitis or nasal allergy is a condition currently underdiagnosed via conventional systemic allergen testing.
NAR patients with a history of seasonality, pollen reactivity, identifiable triggers, additional sites of allergic disease (asthma, dermatitis) and family history of atopy should be considered for local allergen assessment. These patients need to be identified as they will benefit from allergy treatment such as immunotherapy.
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